Diary - News
All news Imaxio receives scientific advice from the European Medicines Agency
Imaxio plans to make IMX836 reach the clinic by early 2018
Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.
This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836.
